Akebia Therapeutics, Inc.
AKBA
$3.19
$0.072.24%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 16.75% | -1.24% | -17.70% | -12.53% | -13.13% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 16.75% | -1.24% | -17.70% | -12.53% | -13.13% |
| Cost of Revenue | 10.45% | -0.73% | -36.45% | 328.94% | 236.63% |
| Gross Profit | 18.05% | -1.34% | -12.93% | -29.92% | -24.65% |
| SG&A Expenses | 5.96% | 6.19% | 6.30% | -0.38% | -11.75% |
| Depreciation & Amortization | -50.00% | -25.00% | 0.00% | 0.00% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -4.08% | -8.37% | -14.02% | -5.97% | -20.04% |
| Operating Income | 116.23% | 48.48% | -2.17% | -55.99% | 44.01% |
| Income Before Tax | 9.79% | -5.30% | -33.68% | 21.53% | 58.82% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 9.79% | -5.30% | -33.68% | 21.53% | 58.82% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 9.79% | -5.30% | -33.68% | 21.53% | 58.82% |
| EBIT | 116.23% | 48.48% | -2.17% | -55.99% | 44.01% |
| EBITDA | 376.03% | 162.46% | -16.55% | -67.82% | 125.53% |
| EPS Basic | 14.67% | 3.07% | -17.67% | 29.95% | 61.99% |
| Normalized Basic EPS | 17.80% | 5.88% | -13.53% | -47.29% | 47.27% |
| EPS Diluted | 15.59% | 4.03% | -18.46% | 30.25% | 61.90% |
| Normalized Diluted EPS | 17.37% | 5.49% | -13.53% | -47.29% | 47.27% |
| Average Basic Shares Outstanding | 16.93% | 13.54% | 12.52% | 9.55% | 7.22% |
| Average Diluted Shares Outstanding | 18.69% | 14.25% | 12.44% | 9.63% | 7.30% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |